Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection

AIDS

Volumn 22, Issue 2, 2008, Pages 275-279

  Tashima, Karen ^a,i   Staszewski, Schlomo ^b   Nelson, Mark ^c   Rachlis, Anita ^d   Skiest, Daniel ^e   Stryker, Richard ^f   Bessen, Laura ^g   Overfield, Sandra ^g   Ruiz, Nancy ^g   Wirtz, Victoria ^h  

^a MIRIAM HOSPITAL   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e BAYSTATE MEDICAL CENTER   (United States)

^f Tower ID Medical Associates ^*  (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

ⁱ BROWN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Efavirenz; Indinavir; Nonnucleoside reverse transcriptase inhibitors

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FLANK PAIN; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRANULOCYTOPENIA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; KIDNEY PAIN; LONG TERM CARE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MENTAL DISEASE; NAUSEA; NEPHROLITHIASIS; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 37549064319     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f21b9d     Document Type: Article

References (12)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-733.
2. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
3. Van Sighem AI, Van De Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17:2227-2236.
4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
5. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf Accessed: 16 January 2007.
6. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865- 1873.
7. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
8. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003; 17:2345-2349.
9. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18:775-779.
10. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
11. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-2315.
12. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.